(19)
(11) EP 4 824 288 A1

(12)

(43) Date of publication:
21.10.2026 Bulletin 2026/43

(21) Application number: 25817712.0

(22) Date of filing: 04.11.2025
(51) International Patent Classification (IPC): 
C12Q 1/6886(2018.01)
(52) Cooperative Patent Classification (CPC):
C12Q 1/6886; C12Q 2600/156
(86) International application number:
PCT/US2025/053913
(87) International publication number:
WO 2026/097062 (07.05.2026 Gazette 2026/19)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH LA MA MD TN

(30) Priority: 04.11.2024 US 202463716165 P

(71) Applicants:
  • Dana-Farber Cancer Institute, Inc.
    Boston, Massachusetts 02215 (US)
  • The General Hospital Corporation
    Boston, Massachusetts 02114 (US)

(72) Inventors:
  • GHOBRIAL, Irene
    Boston, Massachusetts 02215-5450 (US)
  • ALBERGE, Jean-Baptiste
    Boston, Massachusetts 02215-5450 (US)
  • TOENGES, Rosa
    Boston, Massachusetts 02215-5450 (US)
  • GETZ, Gad
    Boston, Massachusetts 02114 (US)
  • IEMURA, Tomoki
    Boston, Massachusetts 02215-5450 (US)

(74) Representative: Elkington and Fife LLP 
Prospect House 8 Pembroke Road
Sevenoaks, Kent TN13 1XR
Sevenoaks, Kent TN13 1XR (GB)

   


(54) GENOMIC PROFILING OF CELLS TO MONITOR MINIMUM RESIDUAL DISEASE